Case Report: The effect of intravenous and oral antibiotics on the gut microbiome and breath volatile organic compounds over one year.
Case Report: The effect of intravenous and oral antibiotics on the gut microbiome and breath volatile organic compounds over one year.
复制标题
DOI：
10.12688/wellcomeopenres.17450.3
复制
发表时间：
2022
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
背景资料：抗菌素耐药性（AMR）是一个全球性的问题，更好地了解肠道微生物组，一个已知的AMR“放大器”，可以让未来的临床医生定制治疗，以尽量减少这种风险，并提供个性化的医疗方法。为了检查肠道微生物组，患者需要提供粪便样本;需要找到更方便和更便宜的解决方案。方法：作为观察给药途径如何影响接受感染常规临床管理的NHS患者的肠道微生物组的试点研究的一部分，我们假设对肠道微生物组的影响随所用抗生素的途径和代谢而变化，并且这些变化可以反映在呼吸代谢物中。我们提出了一个病例报告，患者具有不寻常的临床病史，以及呼吸代谢物和肠道微生物组数据之前，期间和之后的抗生素治疗超过一年。 结果如下：我们注意到患者肠道微生物组中的优势拟杆菌菌株在治疗前和治疗后样本之间发生了变化，沿着呼吸代谢物组成的变化。 结论：这项研究为类似的未来工作提供了一个框架，并强调了进一步研究微生物肠道群落变化与抗菌剂暴露、患者临床状态和人类呼吸代谢物之间关系的必要性。
Background: Antimicrobial resistance (AMR) is a global concern and better understanding of the gut microbiome, a known ‘amplifier’ of AMR, may allow future clinicians to tailor therapy to minimise this risk and offer a personalised medicine approach. To examine the gut microbiome, patients are required to provide faecal samples; more convenient and cheaper solutions need to be found. Methods: As part of a pilot study looking at how routes of administration affect the gut microbiome in NHS patients undergoing routine clinical management for infections, we hypothesised that effects on the gut microbiome varied with the route and metabolism of antibiotic used, and these changes may be reflected in breath metabolites. We present a case report of a patient with an unusual clinical history, alongside breath metabolite and gut microbiome data taken before, during and after antibiotic therapy over a period of one year. Results: We noted a shift in the dominant Bacteroides strain in the patient’s gut microbiome between pre- and post-therapy samples, along with an alteration in the composition of breath metabolites. Conclusions: This study provides a framework for similar future work and highlights the need for further research on the relationships between changes in microbial gut communities and antimicrobial exposure, patient clinical status, and the metabolites of human breath.